Figure 2.

A summary of the process of obtaining and exploiting iPSC-derived neural cells. Somatic cells, such as peripheral blood mononuclear cells and fibroblasts, are typically collected from persons, as these cells are easy and not excessively painful to obtain. After their collection, these cells have different fates: (1) They can be reprogrammed into iPSCs through delivery strategies that include episomal vectors, non-integrating viral vectors, transient DNA transfection, transposons, and protein transduction. Therefore, these cells are forced to express specific transcription factors that reprogram the cells into a pluripotent state (e.g., SOX2, OCT4, and others highlighted in the image). The exposure to lineage-specific neural induction factors promotes the differentiation into neural cells. (2) They can be induced into neural cells in a process called transdifferentiation. This can be achieved through the overexpression of transcription factors, miRNAs, and exposure to chemical cocktails/direct conversion factors that mimic the signaling environment of the developing brain (growth factors and other signaling molecules [37,38]). Depending on the study’s needs, neural cells can be attained in 2D models or more complex 3D models that include brain organoids alone or connected to other organoids on platforms commonly known as organoids-on-a-chip, which can aid drug discovery and evaluate drug efficacy as well as some parameters, including toxicity. Several teams have transplanted iPSC-derived neuronal cells into the brains of mice to understand the peculiarities of circuit dynamics, and humans have already received iPSC-derived cellular transplants [39,40,41]. Adapted from [42]. Figure created with Microsoft PowerPoint^® (2016) BioRender.com (Accessed on 25 October 2022).